24 research outputs found

    Flamingo Vol. III N 4

    Get PDF
    Schmitz. Cover. Picture. 0. Octopus. The Creed of a Frosh. Poem. 4. Widow. Chanson Du Frosh. Poem. 4. Widow. Untitled. Prose. 4. W.M.P. The College Creed. Prose. 4. Anonymous. SHE\u27S GOT THE CLOTHES, THIS FROSH SO FINE, AND HEAVEN KNOWS SHE\u27S GOT THE LINE. SHE\u27S TEETH OF PEARL THAT OFTEN SHOW. HER HAIR WOULD CURL IF IT COULD GROW. WITH ME SHE\u27S IT, GETS BY IMMENSE— BUT I MUST ADMIT SHE\u27S GOT NO SENSE. Picture. 5. Schmitz. SHADES OF THE SUMMER RESORTSOME, ER, KIDD. Picture. 6. Holt, Kilburn. Priest and Levite. Prose. 7. Anonymous. Commentary on a Poem. Prose. 9. Anonymous. Address to an Idle Dream. Poem. 10. Anonymous. Apology. Poem. 10. Uber, D. ONCE MEN LIKED THE GIRLS WHOSE ACQUAINTANCE THEY MADE FOR THE SHY, BASHFUL GLANCES THEY MET. BUT NOW IT\u27S THE HANG OF THE EARRINGS OF JADE, AND THE TILT OF THE CIGARETTE. Picture. 11. K.K.H. Helpful Hints for Foggy Freshmen. Prose. 11. Anonymous. Sonnet in Slang. Prose. 11. Anonymous. Untitled. Prose. 11. Anonymous. Untitled. Prose. 11. Anonymous. Untitled. Prose. 11. Clyde. CAN YOU FIGHT? NOT WITH A WOMAN. COME ON THEN YOU PIE-FACE! . Picture. 11. Anonymous. VITRIOLA RECORDS FOR SEPTEMBER. Prose. 12. Anonymous. Untitled. Prose. 12. Anonymous. Untitled. Prose. 12. Anonymous. Untitled. Prose. 12. Anonymous. Untitled. Prose. 12. E.B. Chapel Cherubs. Picture. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. DO YOU THINK YOU COULD CARE FOR A CHAP LIKE ME? I THINK SO—IF HE WASN\u27T TOO MUCH LIKE YOU. Picture. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. Untitled. Prose. 13. Anonymous. BASIC PLOT FOR SOCIETY DRAMA. Prose. 13. Anonymous. Untitled. Prose. 14. Anonymous. Editor. Picture. 15. Bridge. Denison Comics. Picture. 16. Ubersax. I HAVE BAD NEWS FOE YOU, CLARENCE. SO? YES. I VISITED A FORTUNE TELLER\u27S THIS AFTERNOON, AND SHE TOLD ME THAT I AM GOING TO MARRY A HANDSOME MAN. Picture. 18. Anonymous. The Career of a Good Joke. Prose. 18. W.M.P. Gentle Hints on Curriculum-Synopsis of Popular Courses. Prose. 18. Anonymous. Untitled. Prose. 18. Anonymous. MAY— WOULD YOU WEAR A RENTED BATHING SUIT? JUNE-\u27TT DEPENDS WHERE THE RENT WAS. Picture. 18. Anonymous. Untitled. Poem. 18. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. Untitled. Prose. 19. Anonymous. A READ-LETTER DAY AT THE SEM THIS MONTH. Picture. 19. Anonymous. Famous Greens. Prose. 19. Anonymous. TIE— HOW CAN I THICKEN MY HAIR? CURLS— TRY MOLASSES AND FLOUR. Picture. 19. Anonymous. \u27Twas Ever Thus! Poem. 19. Anonymous. Untitled. Prose. 22. Anonymous. Untitled. Prose. 22. Anonymous. Untitled. Prose. 22. Anonymous. Untitled. Prose. 22. Anonymous. Untitled. Prose. 22. Anonymous. Untitled. Prose. 22. Schmitz. POPULAR COURSE IN TENNYSON. Picture. 23. Purple Cow. Untitled. Prose. 24. Purple Parrot. Heard After Vacation. Prose. 24. Octopus. The Cost of Custom. Prose. 24. Purple Cow. Untitled. Prose. 24. Chaparral. All That Glitters-. Prose. 24. Jack-0-Lantern. Untitled. Prose. 24. Juggler. Untitled. Prose. 24. Reel, Virginia. Untitled. Prose. 24. Anonymous. Oh Gosh! Prose. 25. Brown Jug. Untitled. Prose. 25. Orange Peel. Try and Laugh This Off. Prose. 25. Widow. Untitled. Prose. 25. Banter. Untitled. Prose. 25. Punch Bowl. Extract From Mythology. Prose. 26. Dodo. Untitled. Prose. 26. Puppet. Untitled. Prose. 26. Orange Owl. PAGE MUELLER. Prose. 26. Juggler. Untitled. Prose. 26. Widow. Untitled. Prose. 26. Gargoyle. Untitled. Prose. 26. The Cougar\u27s Paw. The Devil\u27s Dictionary. Prose. 27. Chaparral. Where Did IO Dine? Prose. 27. Octopus. Untitled. Prose. 27. Malteaser. Untitled. Prose. 27. Widow. Untitled. Prose. 27. Chaparral. Untitled. Prose. 27. Malteaser. Untitled. Prose. 27. Mirror. Untitled. Prose. 28. Chaparral. Untitled. Prose. 28. Widow. Higher Mathematics. Prose. 28. Cougar\u27s Paw. Untitled. Prose. 28. Reel, Virginia. Untitled. Prose. 28. Tiger. This May Be New To Someone. Prose. 28. Dodo. Untitled. Prose. 28. Purple Cow. Untitled. Prose. 28. Widow. Page Red Stone. Prose. 28. Dodo. Untitled. Prose. 28. Anonymous. Their Idea of Something Funny. Prose. 29. Anonymous. Untitled. Prose. 29. Garber, Jock. OUR QUESTIONABLE DEPARTMENT. Prose. 30. Brown Jug. Untitled. Prose. 31. Cougar\u27s Paw. Untitled. Prose. 31. Anonymous. Untitled. Prose. 32. Dodo. Untitled. Prose. 32. Purple Cow. Untitled. Prose. 32

    Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    Get PDF
    Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection

    Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    Get PDF
    Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Patient and stakeholder engagement learnings: PREP-IT as a case study

    Get PDF

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    From Body Reform to Reforming the Body Politic: Transcendentalism and the Militant Antislavery Career of Thomas Wentworth Higginson

    No full text

    Thigh-length compression stockings and DVT after stroke

    Get PDF
    Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease
    corecore